Post hoc analysis of PULSAR data shows sustained fluid control with Eylea HD

BARCELONA, Spain — A post hoc analysis of PULSAR trial data showed sustained fluid control at 2 years with fewer injections and longer...
6 days ago
from: Healio

Aflibercept, Bayer, Central retinal vein occlusion, Regeneron Pharmaceuticals

More about this

- EYLEA HD achieves comparable vision gains with fewer doses
TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent biotechnology company with a market...
from: Investing.com

- Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial
For patients it could mean less injections at comparable efficacy and safety, the company said.
from: WSJ